Merck | Contract Pharma

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck | Contract Pharma

Search by

Merck

Company Headquarters

250 Frankfurter Straße, Darmstadt, HE, 64293, DE

Driving Directions Phone: View Phone

View website

Request more information from Merck

Request more information from Merck

Yes, Please subscribe me to your weekly eNewsletters and Alerts

Yes, I wish to receive special promotions and offers from your affiliates.

Yes, I would like to learn more about Merck. Please contact me by Phone or Email

By completing this form, you are accepting our Terms of Use and Privacy Policy.

Categories from Merck

Biologics Process Development

Cell Culture Media Development

Chemicals and Raw Materials

Contract Manufacturing

Custom Manufacturing

Custom Media Development

Custom Synthesis

Excipients

Gene Therapy & Testing Protocols

Manufacturing, Antibody-Drug Conjugates

Manufacturing, API

Manufacturing, API, High Potency

Manufacturing, Custom

Manufacturing, Vaccines

Validation, Services

Library

The Developability Classification System (DCS)

White Papers / Tech Papers

The Developability Classification System (DCS)

Enabling an Optimized Approach for Formulation of Poorly Soluble Molecules

Released By Merck

The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

White Papers / Tech Papers

The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations. This white paper evaluates viscosity-reducing capacities.

Released By Merck

Addressing Handling Challenges of Chemicals by Dry Granulation

Sponsored Content

Addressing Handling Challenges of Chemicals by Dry Granulation

Dry granulation can be a method to overcome caking issues and improve handling of buffers, salts and stabilizing chemicals during pharmaceutical manufacturing.

Released By Merck

Shaping the Future of Formulation Development with Melt-based 3D Printing Technologies

White Papers / Tech Papers

Shaping the Future of Formulation Development with Melt-based 3D Printing Technologies

In this white paper, the use of 3D printing is explored, with a focus on enhancement of bioavailability of APIs in solid dispersions.

Released By Merck

Establishing Commercial Manufacturing Services for Antibody-Drug Conjugates

Sponsored Content

Establishing Commercial Manufacturing Services for Antibody-Drug Conjugates

Learn how to properly structure your development work, perform a thorough process risk assessment and prepare for pre-approval inspection audit.

Released By Merck

The Evolution of Antibody-Drug Manufacturing

White Papers / Tech Papers

The Evolution of Antibody-Drug Manufacturing

Download the FREE White Paper Released by MilliporeSigma.

Released By Merck

Related Content

protagene merck

Collaborations & Alliances

ProtaGene Teams With MilliporeSigma on End-to-End Testing

ProtaGene’s expertise in advanced protein characterization and early-stage drug product characterization is complemented by MilliporeSigma’s GMP testing capabilities and global regulatory experience.

By: Charlie Sternberg

millipore jsr

Breaking News

MilliporeSigma to Acquire the Chromatography Business of JSR Life Sciences

Will expand its downstream processing portfolio with advanced Protein A chromatography capabilities.

By: Charlie Sternberg

milliporesigma merck

Breaking News

MilliporeSigma Introduces Automated Assay Workstation

Automates routine laboratory experiments previously performed manually.

By: Charlie Sternberg

Simtra-MilliporeSigma

Collaborations & Alliances

Simtra BioPharma Solutions & MilliporeSigma Enter Strategic Alliance

The companies partner on antibody drug conjugates, drug substance, and drug product manufacturing services.

By: Rachel Klemovitch

283_main

Breaking News

MilliporeSigma Invests $76M to Expand Bioconjugation Facility in Missouri

Will grow its ADC manufacturing capabilities and triple existing capacity.

359_main

Breaking News

MilliporeSigma Opens €290M CDMO Facility in Rockville, MD

Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building.

730_main

Breaking News

MilliporeSigma Launches Mobius ADC Reactor

Addresses the unique challenges associated with ADC manufacturing, providing biopharmaceutical companies with a more efficient and safer solution.

901_main

Breaking News

MilliporeSigma Closes Acquisition of Mirus Bio

Adding Mirus Bio’s transfection reagents strengthens MilliporeSigma's upstream portfolio and allows for an integrated viral vector manufacturing offering.

610_main

Breaking News

MilliporeSigma Invests €62M in Quality Control Facility in Germany

Site will bring together approximately 135 employees across several departments into one state-of-the-art space.

570_main

Collaborations & Alliances

MilliporeSigma Contributes to Advancing Parkinson’s Research

Makes its immunoassay technology available to the scientific community through support from The Michael J. Fox Foundation for Parkinson's Research.

204_main

Breaking News

MilliporeSigma Agrees to Acquire Mirus Bio for $600M

Mirus Bio develops & commercializes transfection reagents, which play a critical role in the production of viral vector-based gene therapies.

xr:d:DAGB2ySZ84A:2,j:3316199480307702974,t:24040819

Breaking News

MilliporeSigma Invests €300M in New Bioprocessing Facility in South Korea

Will support biotech and pharmaceutical companies in process development, clinical research, and commercial manufacturing of biologics.

558_main

VideoBites

Contract Pharma Sits Down with Josselyn Haas Durr of MilliporeSigma

Manufacturing Science and Technology Manager discusses M Lab Collaboration Centers and addressing customers pain points.

952_main

Breaking News

MilliporeSigma Expands Biologics Testing Center in Shanghai

New labs complete 2nd phase of company’s €29 million Biologics Testing Center opened in 2022.

774_main

Breaking News

MilliporeSigma Launches Integrated mRNA Services

Opens two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.